Results 51 to 60 of about 161,983 (298)

Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness

Frontiers in Immunology, 2023
Immune checkpoint blockade represents the latest revolution in cancer treatment by substantially increasing patients’ lifetime and quality of life in multiple neoplastic pathologies.
Chiara Ursino, Cécile Mouric, Laurent Gros, Nathalie Bonnefoy, Julien Faget   +4 more
doaj   +1 more source

The Cellular and Molecular Immunotherapy in Prostate Cancer

Vaccines, 2022
In recent history, immunotherapy has become a viable cancer therapeutic option. However, over many years, its tenets have changed, and it now comprises a range of cancer-focused immunotherapies. Clinical trials are currently looking into monotherapies or
Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, D. S. Prabakaran, Raja Ganesan, Kaviyarasi Renu, Abhijit Dey, Balachandar Vellingiri, Sabariswaran Kandasamy, Thiyagarajan Ramesh, Abilash Valsala Gopalakrishnan   +9 more
doaj   +1 more source

The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma

Biomedicines, 2022
Immunotherapies with immune checkpoint inhibitors or adoptive cell transfer have become powerful tools to treat cancer. These treatments act via overcoming or alleviating tumor-induced immunosuppression, thereby enabling effective tumor clearance ...
Mitrajit Ghosh, Anna M. Lenkiewicz, Bozena Kaminska   +2 more
doaj   +1 more source

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Journal for ImmunoTherapy of Cancer, 2022
Background This phase 1b study (NCT02323191) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of colony-stimulating factor-1 receptor-blocking monoclonal antibody (mAb) emactuzumab in combination with the programmed cell ...
C. Gomez-Roca, P. Cassier, D. Zamarin, J. Machiels, Jose Luis Perez Gracia, Stephen F. Hodi, Á. Taus, María Martínez García, V. Boni, J. Eder, Navid Hafez, R. Sullivan, D. McDermott, S. Champiat, S. Aspeslagh, C. Terret, A. Jegg, W. Jacob, M. Cannarile, Carola H. Ries, Konstanty Korski, F. Michielin, R. Christen, G. Babitzki, Carl Watson, G. Meneses-Lorente, M. Weisser, D. Rüttinger, J. Delord, A. Marabelle, Twitter Valentina, ValentinaBoni7   +31 more
semanticscholar   +1 more source

Immune checkpoint: The novel target for antitumor therapy

Genes and Diseases, 2021
Inhibitory checkpoint molecules include programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), cytotoxic T lymphocyte antigen-4 (CTLA-4), human endogenous retrovirus-H Long terminal repeat-associating 2 (HHLA2), B7 homolog 4 protein (B7 ...
Xianghu Jiang, Guohong Liu, Yirong Li, Yunbao Pan   +3 more
doaj   +1 more source

Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology

Frontiers in Oncology, 2018
The tumor microenvironment (TME) is a multifaceted ecosystem characterized by profound cellular heterogeneity, dynamicity, and complex intercellular cross-talk.
Francesca Finotello, Federica Eduati
doaj   +1 more source

Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

npj Precision Oncology, 2021
A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer.
Yves Boucher, Ashwin S. Kumar, Jessica M. Posada, Evisa Gjini, Kathleen Pfaff, Mikel Lipschitz, Ana Lako, Dan G. Duda, Scott J. Rodig, F. Stephen Hodi, Rakesh K. Jain   +10 more
doaj   +1 more source

Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer

Journal for ImmunoTherapy of Cancer, 2022
Background Tumor infiltrating lymphocytes (TILs) reflect adaptive antitumor immune responses in cancer and are generally associated with favorable prognosis.
Miguel Lopez de Rodas, Venkata V Nagineni, Arvind Ravi, I. Datar, M. Mino‐Kenudson, Germán Corredor, Cristian Barrera, Lindsey Behlman, D. Rimm, R. Herbst, A. Madabhushi, J. Riess, V. Velcheti, M. Hellmann, J. Gainor, K. Schalper   +15 more
semanticscholar   +1 more source

Trial watch: Toll-like receptor ligands in cancer therapy

OncoImmunology, 2023
Accumulating evidence indicates that Toll-like receptor (TLR) agonists proficiently (re)instore cancer immunosurveillance as immunological adjuvants. So far, three TLR agonists have been approved by regulatory agencies for use in oncological applications.
Julie Le Naour, Guido Kroemer
doaj   +1 more source

CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas

Nature Communications, 2022
Tumor-infiltrating CD8 + T cells progressively lose functionality and fail to reject tumors. The underlying mechanism and re-programing induced by checkpoint blockers are incompletely understood.
Leticia Laura Niborski, Paul Gueguen, Mengliang Ye, Allan Thiolat, Rodrigo Nalio Ramos, Pamela Caudana, Jordan Denizeau, Ludovic Colombeau, Raphaël Rodriguez, Christel Goudot, Jean-Michel Luccarini, Anne Soudé, Bruno Bournique, Pierre Broqua, Luigia Pace, Sylvain Baulande, Christine Sedlik, Jean-Pierre Quivy, Geneviève Almouzni, José L. Cohen, Elina Zueva, Joshua J. Waterfall, Sebastian Amigorena, Eliane Piaggio   +23 more
doaj   +1 more source